ArticleBiosensors2026
Explainable AI-Assisted Label-Free Raman Biosensing Reveals Therapy-Associated Spectral Signatures in Melanoma Tumors.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sensitive detection of treatment-associated Raman spectral alterations in tumor tissues remains challenging, particularly when such changes are not readily apparent from conventional morphological evaluation. Here, we developed a label-free Raman biosensing strategy combined with explainable machine learning to characterise treatment-associated spectral signatures in melanoma tumours. A B16-F10 melanoma-bearing mouse model was used to compare untreated and PBS-treated controls with cohorts receiving immune checkpoint blockade, anti-angiogenic intervention, or combination therapy. Raman spectra were acquired from multiple spatial regions of melanoma tissues and analyzed using nonlinear dimensionality reduction, supervised classification, and SHAP-based feature interpretation. Although cohort-averaged spectra showed substantial overlap, multivariate analysis revealed treatment-dependent spectral organization, with the combination-treatment cohort showing the most compact and distinguishable spectral profile. Supervised models, including convolutional neural networks, support vector machines, and k-nearest neighbors, further supported the reproducibility of treatment-associated Raman signatures when evaluated using mouse-level validation strategies. SHAP analysis identified discriminative Raman features mainly located within lipid, phospholipid, ester, protein, and collagen-associated vibrational domains, suggesting potential contributions from metabolic- and extracellular-matrix-related biochemical components to treatment-associated spectral discrimination. These findings indicate that Raman spectroscopy integrated with explainable machine learning provides a sensitive, label-free method for distinguishing treatment-associated spectral differences among melanoma tissues. The proposed approach may serve as a complementary spectroscopic tool alongside conventional histological and molecular analyses for investigating treatment-associated tissue-state alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.